Kymab, a Cambridge, UK-based monoclonal antibody biopharmaceutical company, raised US$40m in Series B financing.
The company intends to use the funds to advance its Kymouse™ platform and proprietary pipeline of therapeutic human monoclonal antibodies. It will also collaborate with the Gates Foundation and its partners on vaccine antigen discovery research and development with an initial focus on malaria and HIV.
Led by Dr David Chiswell, Chairman, and Dr Christian Grøndahl, Chief Executive Officer, Kymab is using the Kymouse™ transgenic human antibody platform to discover and develop fully human monoclonal antibody drugs.
To complement the growth of its internal pipeline of programs, the company will seek to enter into a limited number of strategic collaborations to identify and develop therapeutic antibodies in a range of diseases. In addition, Kymab has established Kymab Access, a program that enables academic researchers to pursue the discovery and development of novel human monoclonal antibody therapeutics and vaccines by partnering with Kymab and its antibody technology.